JPWO2019200202A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019200202A5 JPWO2019200202A5 JP2020555323A JP2020555323A JPWO2019200202A5 JP WO2019200202 A5 JPWO2019200202 A5 JP WO2019200202A5 JP 2020555323 A JP2020555323 A JP 2020555323A JP 2020555323 A JP2020555323 A JP 2020555323A JP WO2019200202 A5 JPWO2019200202 A5 JP WO2019200202A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- compound
- heterocyclyl
- substituted
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 176
- 125000000623 heterocyclic group Chemical group 0.000 claims description 59
- 125000000217 alkyl group Chemical group 0.000 claims description 46
- 125000001072 heteroaryl group Chemical group 0.000 claims description 27
- 125000003118 aryl group Chemical group 0.000 claims description 25
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 19
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- -1 alkylene-cycloalkyl Chemical group 0.000 claims description 14
- 125000001424 substituent group Chemical group 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 8
- 125000003107 substituted aryl group Chemical group 0.000 claims description 7
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 208000005577 Gastroenteritis Diseases 0.000 claims description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- 208000037976 chronic inflammation Diseases 0.000 claims description 5
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 5
- 206010009887 colitis Diseases 0.000 claims description 5
- 210000004072 lung Anatomy 0.000 claims description 5
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- 208000015943 Coeliac disease Diseases 0.000 claims description 4
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims description 4
- 208000003167 cholangitis Diseases 0.000 claims description 4
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 4
- 206010016654 Fibrosis Diseases 0.000 claims description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 3
- 201000003146 cystitis Diseases 0.000 claims description 3
- 230000004761 fibrosis Effects 0.000 claims description 3
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 206010006262 Breast inflammation Diseases 0.000 claims description 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 206010009137 Chronic sinusitis Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000027932 Collagen disease Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 230000003872 anastomosis Effects 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 206010006451 bronchitis Diseases 0.000 claims description 2
- 208000007451 chronic bronchitis Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims description 2
- 208000008609 collagenous colitis Diseases 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 208000037902 enteropathy Diseases 0.000 claims description 2
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 claims description 2
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims description 2
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims description 2
- 208000009326 ileitis Diseases 0.000 claims description 2
- 208000028774 intestinal disease Diseases 0.000 claims description 2
- 208000004396 mastitis Diseases 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- 208000008275 microscopic colitis Diseases 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 229910052731 fluorine Chemical group 0.000 claims 1
- 239000011737 fluorine Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 238000000034 method Methods 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000002389 Pouchitis Diseases 0.000 description 1
- 235000019000 fluorine Nutrition 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000010880 proctocolectomy Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023174330A JP7700193B2 (ja) | 2018-04-12 | 2023-10-06 | ヒトインテグリンα４β７のアンタゴニスト |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862656742P | 2018-04-12 | 2018-04-12 | |
| US62/656,742 | 2018-04-12 | ||
| PCT/US2019/027141 WO2019200202A1 (en) | 2018-04-12 | 2019-04-12 | Antagonists of human integrin (alpha4)(beta7) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023174330A Division JP7700193B2 (ja) | 2018-04-12 | 2023-10-06 | ヒトインテグリンα４β７のアンタゴニスト |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021531234A JP2021531234A (ja) | 2021-11-18 |
| JP2021531234A5 JP2021531234A5 (https=) | 2022-04-20 |
| JPWO2019200202A5 true JPWO2019200202A5 (https=) | 2022-04-20 |
| JP7365358B2 JP7365358B2 (ja) | 2023-10-19 |
Family
ID=68161020
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555323A Active JP7365358B2 (ja) | 2018-04-12 | 2019-04-12 | ヒトインテグリンα４β７のアンタゴニスト |
| JP2023174330A Active JP7700193B2 (ja) | 2018-04-12 | 2023-10-06 | ヒトインテグリンα４β７のアンタゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023174330A Active JP7700193B2 (ja) | 2018-04-12 | 2023-10-06 | ヒトインテグリンα４β７のアンタゴニスト |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US10759756B2 (https=) |
| EP (1) | EP3773573B1 (https=) |
| JP (2) | JP7365358B2 (https=) |
| CN (1) | CN112312910A (https=) |
| AR (1) | AR114489A1 (https=) |
| MA (1) | MA52249A (https=) |
| TW (2) | TW202528300A (https=) |
| WO (1) | WO2019200202A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7365358B2 (ja) * | 2018-04-12 | 2023-10-19 | モーフィック セラピューティック，インコーポレイテッド | ヒトインテグリンα４β７のアンタゴニスト |
| CN112969700B (zh) | 2018-10-30 | 2024-08-20 | 吉利德科学公司 | 作为α4β7整合素抑制剂的咪唑并吡啶衍生物 |
| KR102659859B1 (ko) | 2018-10-30 | 2024-04-25 | 길리애드 사이언시즈, 인코포레이티드 | 알파4β7 인테그린의 억제를 위한 화합물 |
| AU2019373242B2 (en) | 2018-10-30 | 2023-07-13 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| EP4541422A3 (en) | 2018-10-30 | 2025-06-25 | Gilead Sciences, Inc. | Quinoline derivatives as alpha4beta7 integrin inhibitors |
| KR102908219B1 (ko) | 2019-08-14 | 2026-01-08 | 길리애드 사이언시즈, 인코포레이티드 | 알파 4 베타 7 인테그린의 저해용 화합물 |
| WO2021076890A1 (en) * | 2019-10-16 | 2021-04-22 | Morphic Therapeutic, Inc. | INHIBITING HUMAN INTEGRIN α4β7 |
| IL302906A (en) * | 2020-11-20 | 2023-07-01 | Denali Therapeutics Inc | Compounds, compositions, and methods |
| CN118591535A (zh) * | 2021-12-27 | 2024-09-03 | 西藏海思科制药有限公司 | 一种丙酸衍生物及其在医药上的应用 |
| JP2025530250A (ja) * | 2022-09-09 | 2025-09-11 | シーザン ハイスーク ファーマシューティカル カンパニー リミテッド | プロピオン酸誘導体及びその医薬的な応用 |
| KR20250120367A (ko) * | 2022-12-22 | 2025-08-08 | 신테라, 인크. | 알파4 베타7 인테그린 안타고니스트 및 이의 용도 |
| JP2026506997A (ja) * | 2023-02-21 | 2026-02-27 | シーフォーエックス・ディスカバリー・リミテッド | 大環状アルファ４ベータ７インテグリン阻害剤 |
| WO2025026955A1 (en) * | 2023-07-28 | 2025-02-06 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| TW202515852A (zh) * | 2023-09-15 | 2025-04-16 | 美商莫菲克醫療股份有限公司 | 抑制人類整合素α４β７ |
| WO2025176107A1 (zh) * | 2024-02-20 | 2025-08-28 | 西藏海思科制药有限公司 | 一种吡啶酮衍生物及其在医药上的应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| CA2159450C (en) * | 1993-03-31 | 2002-01-08 | Norman Anthony Abood | 1-amidinophenyl-pyrrolidones piperidinones azetinones as platelet aggregation inhibitors |
| DE4427979A1 (de) * | 1993-11-15 | 1996-02-15 | Cassella Ag | Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung |
| US5849736A (en) * | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
| BR9408137A (pt) | 1993-11-24 | 1997-08-12 | Du Pont Merck Pharma | Composto éster de prodroga método de tratamento composição farmacêutica e método de inibição |
| DE19622489A1 (de) * | 1996-06-05 | 1997-12-11 | Hoechst Ag | Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters |
| US5981546A (en) * | 1996-08-29 | 1999-11-09 | Merck & Co., Inc. | Integrin antagonists |
| WO1998016524A1 (en) | 1996-10-11 | 1998-04-23 | Cor Therapeutics, Inc. | HETEROCYCLIC DERIVATIVES AS FACTOR Xa INHIBITORS |
| EP0932615A1 (en) | 1996-10-11 | 1999-08-04 | Cor Therapeutics, Inc. | SELECTIVE FACTOR Xa INHIBITORS |
| DE19751251A1 (de) * | 1997-11-19 | 1999-05-20 | Hoechst Marion Roussel De Gmbh | Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate |
| US6645939B1 (en) | 1997-11-24 | 2003-11-11 | Merck & Co., Inc. | Substituted β-alanine derivatives as cell adhesion inhibitors |
| MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
| DE19821483A1 (de) * | 1998-05-14 | 1999-11-18 | Hoechst Marion Roussel De Gmbh | Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| CA2333647A1 (en) * | 1998-06-29 | 2000-01-06 | Dupont Pharmaceuticals Company | Cyclic carbamates and isoxazolidines as iib/iiia antagonists |
| GB9826174D0 (en) * | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
| US6972296B2 (en) | 1999-05-07 | 2005-12-06 | Encysive Pharmaceuticals Inc. | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| US6723711B2 (en) * | 1999-05-07 | 2004-04-20 | Texas Biotechnology Corporation | Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
| BR0010349B1 (pt) * | 1999-05-07 | 2011-10-04 | derivados de ácido propanóico que inibem a ligação de integrinas aos seus receptores. | |
| CA2385882C (en) | 1999-09-24 | 2009-11-24 | Genentech, Inc. | Tyrosine derivatives |
| DE10041423A1 (de) | 2000-08-23 | 2002-03-07 | Merck Patent Gmbh | Biphenylderivate |
| DE10111876A1 (de) * | 2001-03-10 | 2002-09-19 | Aventis Pharma Gmbh | Bis(trifluormethyl)hydantoine als Zwischenprodukte für pharmazeutische Wirkstoffe |
| DE10154280A1 (de) | 2001-11-05 | 2003-05-15 | Wilex Ag | Antagonisten für alpha¶4¶-Integrine |
| PL215263B1 (pl) | 2002-02-25 | 2013-11-29 | Elan Pharm Inc | Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku |
| RS52213B (sr) | 2004-09-03 | 2012-10-31 | Genentech, Inc. | Humanizovani anti-beta7 antagonisti i njihove primene |
| ES2387317T3 (es) | 2005-03-03 | 2012-09-20 | Seedlings Life Science Ventures, Llc. | Procedimiento de control de riesgos de pacientes en tratamiento con natalizumab |
| WO2006126529A1 (ja) | 2005-05-25 | 2006-11-30 | Shionogi & Co., Ltd. | ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体 |
| AU2006254772B2 (en) | 2005-06-09 | 2011-06-02 | Ucb Pharma S.A. | 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament |
| ES2752137T3 (es) | 2006-02-28 | 2020-04-03 | Biogen Ma Inc | Métodos para tratar enfermedades inflamatorias y autoinmunes con natalizumab |
| US20100272680A1 (en) | 2009-02-09 | 2010-10-28 | Subramanian Baskaran | Piperidinyl Cyclic Amido Antiviral Agents |
| EP3412309A1 (en) | 2011-03-31 | 2018-12-12 | F. Hoffmann-La Roche AG | Methods of administering beta7 integrin antagonists |
| EP2903691B1 (en) | 2012-10-05 | 2019-05-22 | F.Hoffmann-La Roche Ag | Methods for diagnosing and treating inflammatory bowel disease |
| KR20220065091A (ko) | 2014-03-27 | 2022-05-19 | 제넨테크, 인크. | 염증성 장 질환의 진단 및 치료 방법 |
| WO2016011940A1 (zh) | 2014-07-25 | 2016-01-28 | 江苏恒瑞医药股份有限公司 | 氮茚-酰胺类衍生物、其制备方法及其在医药上的应用 |
| KR20170120601A (ko) | 2015-02-26 | 2017-10-31 | 제넨테크, 인크. | 인테그린 베타7 길항제 및 크론병을 치료하는 방법 |
| US10246451B2 (en) | 2017-04-26 | 2019-04-02 | Aviara Pharmaceuticals, Inc. | Propionic acid derivatives and methods of use thereof |
| JP7365358B2 (ja) | 2018-04-12 | 2023-10-19 | モーフィック セラピューティック，インコーポレイテッド | ヒトインテグリンα４β７のアンタゴニスト |
| AU2019373242B2 (en) | 2018-10-30 | 2023-07-13 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| KR102659859B1 (ko) | 2018-10-30 | 2024-04-25 | 길리애드 사이언시즈, 인코포레이티드 | 알파4β7 인테그린의 억제를 위한 화합물 |
| CN112969700B (zh) | 2018-10-30 | 2024-08-20 | 吉利德科学公司 | 作为α4β7整合素抑制剂的咪唑并吡啶衍生物 |
| EP4541422A3 (en) | 2018-10-30 | 2025-06-25 | Gilead Sciences, Inc. | Quinoline derivatives as alpha4beta7 integrin inhibitors |
| WO2021076890A1 (en) | 2019-10-16 | 2021-04-22 | Morphic Therapeutic, Inc. | INHIBITING HUMAN INTEGRIN α4β7 |
-
2019
- 2019-04-12 JP JP2020555323A patent/JP7365358B2/ja active Active
- 2019-04-12 EP EP19785592.7A patent/EP3773573B1/en active Active
- 2019-04-12 TW TW113137058A patent/TW202528300A/zh unknown
- 2019-04-12 TW TW108112877A patent/TWI856956B/zh active
- 2019-04-12 WO PCT/US2019/027141 patent/WO2019200202A1/en not_active Ceased
- 2019-04-12 US US16/382,512 patent/US10759756B2/en active Active
- 2019-04-12 CN CN201980033206.5A patent/CN112312910A/zh active Pending
- 2019-04-12 MA MA052249A patent/MA52249A/fr unknown
- 2019-04-12 AR ARP190100980A patent/AR114489A1/es unknown
-
2020
- 2020-07-27 US US16/939,812 patent/US11174228B2/en active Active
-
2021
- 2021-11-12 US US17/525,479 patent/US20220340529A1/en not_active Abandoned
-
2023
- 2023-10-06 JP JP2023174330A patent/JP7700193B2/ja active Active
- 2023-12-22 US US18/394,421 patent/US12221416B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019200202A5 (https=) | ||
| JP2021531234A5 (https=) | ||
| EP2354128A1 (en) | Method for the preparation of rivaroxaban | |
| CN113365997A (zh) | 作为c-Met抑制剂的含嘧啶基团的三并环类化合物 | |
| MXPA05004661A (es) | Procedimientos para preparar oxazolidinonas n-ariladas mediante una reaccion de acoplamiento cruzado catalizada por cobre. | |
| JPWO2021092115A5 (https=) | ||
| EP2163547A1 (en) | Process for the preparation of an oxazolidinone antibacterial agent and intermediates thereof | |
| JPWO2021187531A5 (https=) | ||
| AU2021276066A1 (en) | Process of preparing butyl-(5S)-5-({2-(4-(butoxycarbonyl)phenyl)ethyl}(2-(2-{(3-chloro-4'-(trifluoromethyl)(biphenyl)-4-yl)methoxy}phenyl)ethyl)amino)-5,6,7,8-tetrahydroquinoline-2-carboxylate | |
| CN1119643A (zh) | 杂环-n-氧化物取代的苯甲酰胍、制法、用途及药物 | |
| JP7307282B2 (ja) | ベンゾ２－アザスピロ［４．４］ノナン系化合物及びその使用 | |
| AU2015294840A1 (en) | A process for the preparation of nucleoside phosphoramidate | |
| EP4214190B1 (en) | Method for preparing arylvinylsulphones | |
| TWI894459B (zh) | 製備用於合成鞘胺醇—１—磷酸酯受體促效劑之中間體的方法 | |
| JP2006503053A5 (https=) | ||
| CN101707952A (zh) | 一种制备利伐斯的明的方法及其中间体 | |
| TW202342443A (zh) | 用於製備３－溴－１－（３－氯吡啶－２－基）－４，５－二氫－１ｈ－吡唑－５－甲酸乙酯之方法 | |
| CN114656391B (zh) | 多羟基吡咯烷类化合物及其制备方法和应用 | |
| CN110734430A (zh) | 用于合成取代的γ内酰胺的方法 | |
| CA2009679C (fr) | Procede de preparation de dicarbonate de ditertioalcoyle | |
| EA050475B1 (ru) | Способ синтеза производных нафтиридина и их промежуточных соединений | |
| KR20220071147A (ko) | 트랜스-4-[4-(3-메톡시-4-니트로페닐)-1-피페라지닐]아다만탄-1-올 합성방법 | |
| FR2459263A1 (fr) | Ignifugation du polyacrylonitrile | |
| JPH04234350A (ja) | アクリル酸エステル類の製造方法 | |
| CN107674039A (zh) | 一种可比西他中间体的制备方法 |